GENESIS-PHARMA
12.1.2024 12:37:29 CET | Business Wire | Press release
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify Launches Global Air Travel Fraud Report Revealing Where Booking-Stage Pressure Is Most Concentrated22.4.2026 14:00:00 CEST | Press release
Q1 2026 analysis shows significant variation in prevented fraud rates by origin city, with higher concentrations across parts of Latin America, Africa, the Middle East, and South & Southeast Asia Accertify, a leading unified risk decisioning platform provider, today announced the release of its Global Air Travel Fraud Report: Q1 2026, a quarterly analysis examining how fraud risk in airline bookings varies by route origin across global markets. Based on more than 180 million airline booking transactions processed between January and March 2026, the report analyzes fraud rates by departure city as a proxy for route origin, offering airlines a practical view of where fraud prevention systems are intervening most frequently at the point of booking. The Q1 2026 findings show that fraud risk in airline bookings is unevenly distributed across markets, with meaningful differences emerging by region and by origin city. Routes originating in North America and Australia continue to exhibit consi
NetApp Strengthens its Collaboration with Google Cloud on Unified Google Cloud Storage for File and Block22.4.2026 14:00:00 CEST | Press release
Announced at Next ‘26, Flex Unified service for Google Cloud NetApp Volumes is now generally available NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today shared new innovations that help customers better leverage their enterprise data, by tapping into the benefits of AI with Google Cloud. Enterprises want to use their existing data for AI, but moving and managing that data across multiple environments is complex, slow, and expensive. NetApp is simplifying this with Google Cloud. With Google Cloud NetApp Volumes, customers can run enterprise applications, databases, and AI workloads in the cloud without rearchitecting or rebuilding their environments. “Customers can move their enterprise data, whether block or file, into Google Cloud NetApp Volumes easily, and once it’s there, they can use Google Cloud services, including for AI, directly on that data without needing to move or duplicate it again,” said Pravjit Tiwana, Senior Vice President and General Manager of
NetApp Partners with Google Cloud to Adopt AI-Driven Operations22.4.2026 14:00:00 CEST | Press release
Google Gemini Enterprise drives productivity for NetApp sales and product development NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a strategic evolution in its partnership with Google Cloud, which has enabled enterprises to drive AI innovation with their own data stored in the NetApp data platform. After seeing the productivity and innovation benefits customers experienced using Gemini Enterprise integrated with their data in Google Cloud NetApp Volumes, NetApp has adopted Gemini Enterprise to help increase productivity in its internal product development and sales operations. With the adoption of Google Cloud AI technologies, NetApp is expanding its leadership in enterprise-grade AI innovation, not just enabling AI workloads but acting as an AI practitioner. NetApp customers will benefit from the AI-powered gains in productivity and innovation. “AI is an imperative for enterprise success, and NetApp is committed to leading by example,” said Césa
ExaGrid Named a Finalist for the Storage Awards 202622.4.2026 14:00:00 CEST | Press release
ExaGrid Product Line, Partner Program, and Team Nominated in 16 Categories for “The Storries XXIII” ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 16 categories for the 23rd annual Storage Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422235829/en/ ExaGrid has become a finalist in the following categories: Storage Innovator of the Year Immutable Storage Company of the Year Storage Industry Champion – Commercial Storage Industry Champion – Marketing Channel Excellence Award AI Data Storage Innovator of the Year Cyber Resilient Storage Company of the Year Ransomware Product of the Year Data Protection Company of the Year Enterprise Backup Hardware Vendor of the Year Object Storage Vendor of the Year Storage Optimisation Compan
Samsung Biologics Union Holds First Rally, Warns of May 1 Strike22.4.2026 13:56:00 CEST | Press release
Union estimates about 2,200 participants at one-hour event outside Bio Campus 1 Samsung Biologics’ labor union held its first rally on Tuesday and said it would move ahead with a strike on May 1 if management continues to reject meaningful talks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422754766/en/ Union members gather at a rally organized by the Samsung Biologics labor union outside Bio Campus 1 in Songdo, Incheon, on April 22, ahead of a planned May 1 strike. The rally, held for about an hour outside the main gate of the company’s Bio Campus 1 in Songdo, drew about 2,200 participants, according to the union. The event marks an escalation in a labor dispute that union leaders say is no longer limited to a small number of bargaining items, but instead concerns broader questions about accountability and decision-making within the company. Park Jaesung, chair of the Samsung Biologics union, said management had faile
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom